+
+
Stay Informed
TEER

TRANSCATHETER
EDGE-TO-EDGE REPAIR

Transcatheter edge-to-edge repair (TEER) therapy provides a minimally invasive solution for treating mitral or tricuspid regurgitation and delivers safe, effective and durable outcomes for select patients.

TEER

TRANSCATHETER
EDGE-TO-EDGE REPAIR

Transcatheter edge-to-edge repair (TEER) therapy provides a minimally invasive solution for treating mitral or tricuspid regurgitation and delivers safe, effective and durable outcomes for select patients.

Innovating Transcatheter Edge-to-Edge Repair for Mitral and Tricuspid Valves

MitraClip™ and TriClip™ TEER offer the option of four clip sizes for tailored treatment across a wide range of complex anatomies.1,2

Tailored Repair

MitraClip™ targets mitral regurgitation (MR) and TriClip™ targets tricuspid regurgitation (TR), conditions which, if left untreated, can lead to progressive heart failure and increased mortality risk.14,15

Proven Safety Profile

TEER has demonstrated a strong safety profile across diverse patient populations, with consistent outcomes in both clinical studies and real-world practice.7,13

Backed by robust evidence

Supported by a growing body of randomized trials and real-world clinical data across hundreds of thousands of patients worldwide.14,15

Heart team-driven

Candidacy is determined through a multidisciplinary Heart Team evaluation, and early referral is necessary to give patients the best chance at meaningful improvement.14,15

Sign up for educational TEER resources delivered to your inbox.

Stay on top of current patient selection criteria, clinical evidence, and referral pathways by signing up to receive tailored updates on upcoming webinars, case-based learning, and educational resources.

SIGN UP

The Most Durable Data in TEER

Engineered to Deliver Long-Term Clinical Benefits

Built on a strong foundation of clinical data, MitraClip and TriClip TEER are trusted solutions in structural heart care that support durable outcomes and sustained improvements in patient quality of life.

MR REDUCTION
  • At 5 years, 95% of MitraClip-treated patients in the COAPT Trial experienced MR ≤2+, sustained from 93% at 30 days.5
  • MR ≤1+ was achieved in 93% of patients treated with MitraClip TEER in the EXPAND G4 Study.7

Data not from head-to-head studies.
Data are provided for informational purposes only.

HFH REDUCTION

Heart failure hospitalizations (HFH) reduction shown across multiple studies and in real-world settings.

  • Consistent HFH at 2 years compared to prior TEER studies16
  • 63% reduction in HFH seen at 1 year post MitraClip TEER procedure in the EXPAND Study17
  • 47% relative risk reduction in HFH at 5 years versus GMDT-alone in the COAPT Trial18

GMDT=guideline-directed medical thearpy

IMPROVEMENT IN QUALITY OF LIFE
  • 17-point improvement in KCCQ-OS score from baseline to 2 years with MitraClip TEER in the EXPAND G4 Study, maintained from an 18-point improvement at 30 days.16
  • Large improvement to NYHA Class I/II was sustained at 2 years.16

NYHA=New York Heart Association.

See More Data

MR REDUCTION

* EVEREST II: MR data categorized as Mild (including none/trace), Moderate, and Moderate to Severe (including severe)

HFH Reduction

Improvement in Quality of Life

SIGNIFICANT TR REDUCTION

Significant TR reduction achieved despite high percentages of patients with massive or torrential TR at baseline—across 3 independent studies.

HFH REDUCTION

Now proven to safely reduce HFH risk in two randomized controlled trials.

  • 28% reduction in HFH relative to medical therapy in the TRILUMINATE Pivotal trial8
  • 48% reduction in HFH relative to medical therapy in Tri.Fr12*

HFH=heart failure hospitalizations.
*Tri.Fr is an Investigator Sponsored Study.

LASTING IMPROVEMENT IN HEART FAILURE SYMPTOMS

NYHA class improvements seen at year 1 were maintained through year 3.12 At 1 year, 85% of TRILUMINATE™ Pivotal Trial patients achieved NYHA Class I/II, versus 47% at baseline.13

NYHA=New York Heart Association.

See More Data

TR REDUCTION

HFH REDUCTION

IMPROVEMENT IN QUALITY OF LIFE

TEER Education on Demand

Expert-led sessions to support your TEER education

Access our growing library of TEER educational sessions. Each session is designed to help physicians better understand patient selection, referral pathways, and the latest clinical evidence supporting MitraClip and TriClip TEER therapy.

All Mitraclip Webinars                All TRICLIP Webinars

Engineering Excellence Across Five Generations of TEER

Leading innovation in mitral and tricuspid care

For more than two decades, Abbott has advanced TEER technology through the MitraClip and TriClip TEER systems, helping transform structural heart care worldwide. With hundreds of thousands of patients treated and five generations of innovation, TEER continues to set the standard for safety and performance.

Sign up for updates

Receive TEER updates, clinical insights, and educational resources
from Abbott Structural Heart.

SIGN UP

Refer Your Patient for TEER

When mitral or tricuspid regurgitation is identified in your patient, early referral to a structural heart program can make a meaningful difference in outcomes. MitraClip and TriClip TEER offer a proven, minimally invasive pathway for patients who are symptomatic despite guideline-directed medical therapy, including those at prohibitive or high surgical risk.

DOWNLOAD CLINICAL GUIDELINESFind a Heart Clinic

MAT-2675537 v1.0 | Item approved for U.S. use only.

References
  1. Maisano F. Clip Selection Strategy with 4th Generation MitraClip™: Evidence-Based Recommendations from the Global EXPAND Study. Data presented at PCR London Valves 2022.
  2. Lurz P, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results from the TriClip™ bRIGHT Study. Data presented at Euro PCR 2022
  3. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66(25):2844-2854. doi:10.1016/j.jacc.2015.10.018
  4. EVEREST II randomized controlled trial (RCT). Five year final report. November 2014. Data on File at Abbott.
  5. Stone GW, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388(22):2037-2048. doi:10.1056/NEJMoa2300213
  6. Kar S, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND study. JACC Cardiovasc Interv. 2023;16(5):589–602. doi:10.1016/j.jcin.2023.01.010
  7. von Bardeleben RS, et al. 1-year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from the EXPAND G4 study. JACC Cardiovasc Interv. 2023;16(21):2600-2610. doi:10.1016/j.jcin.2023.09.029
  8. Kar S, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial. Circulation. 2025;151(23):1630–1638. doi:10.1161/CIRCULATIONAHA.125.074536
  9. Donal E, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized clinical trial. JAMA. 2025;333(2):124-132. doi:10.1001/jama.2024.21189
  10. Nickenig G, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE study. JACC Cardiovasc Interv. 2024;17(18):2113-2122. doi:10.1016/j.jcin.2024.05.036
  11. Bekeredjian R. Real-world 2-year results of tricuspid edge-to-edge repair from the bRIGHT study. Presented at EuroPCR 2025; Paris, France.
  12. Donal E, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation — extended follow-up — the Tri.Fr Randomized Clinical Trial. Presented at ACC 2026, March 29, 2026.
  13. Sorajja GW, et al. Transcatheter edge-to-edge repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388(20):1833-1842. doi: 10.1056/NEJMoa2300525
  14. MitraClip G5 Delivery System Instructions for Use.
  15. TriClip G5 Delivery System Instructions for Use.
  16. DeMarco F, et al. Two‑Year Outcomes with the MitraClip G4 System: Results from the EXPAND G4 Study. Data presented at PCR London Valves 2025
  17. Kar S. Core-Lab Adjudicated Contemporary Clinical Outcomes at 1 Year with MitraClip™ (NTR/XTR) System from Global EXPAND Study. Data presented at TCT 2020.
  18. Stone GW. et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med. March 5, 2023. DOI: 10.1056/NEJMOA2300213.
Important Safety Information
  • MitraClip
  • TriClip

  • Rx Only

    MITRACLIP™ CLIP DELIVERY SYSTEM

    INDICATIONS FOR USE

    The MitraClip™ G5 System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.

    The MitraClip™ G5 System, when used with maximally tolerated guideline-directed medical therapy (GDMT), is indicated for the treatment of symptomatic, moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR ≥ Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) ≥ 20% and ≤ 50%, and a left ventricular end systolic dimension (LVESD) ≤ 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

    CONTRAINDICATIONS

    The MitraClip™ G5 System is contraindicated for use in patients with the following conditions:

    • Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation
    • Untreatable hypersensitivity to Implant components (nickel- titanium alloy, cobalt-chromium alloy)
    • Active endocarditis or other active infection of the mitral valve 

    POTENTIAL COMPLICATIONS AND ADVERSE EVENTS

    The following events have been identified as possible complications of the MitraClip™ G5 procedure:
    Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials, and drug reactions to anticoagulation, or antiplatelet drugs, additional treatment/surgery from device-related complications, atrial septal defect, bleeding, blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)), Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias), Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina), Cardiac perforation, Cardiac tamponade, chest pain, death, Dyspnea, Edema, Embolization (device or components of the device), Endocarditis, fever or hyperthermia, Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding, Hypotension / hypertension; Infection including: Septicemia; Mitral valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), dislodgement of previously implanted devices, tissue damage, mitral valve stenosis, worsening, persistent or residual regurgitation, nausea or vomiting, pain, Pericardial effusion, stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA), system organ failure: cardio-respiratory arrest, worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic), Thrombosis, Vascular access complications which may require additional intervention, including: wound dehiscence, bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury, Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism)

  • Rx Only

    TRICLIP™ G5 SYSTEM

    INDICATIONS

    The TriClip™ G5 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The TriClip™ G5 System is contraindicated for use in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

    POTENTIAL ADVERSE EVENTS

    The following events have been identified as possible complications of the TriClip™ G5 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+